Terms: = Thyroid cancer AND MET, RCCP2, 4233, ENSG00000105976, P08581, HGFR, AUTS9 AND Staging
22 results:
1. methionine metabolism and endocrine function of the pituitary gland in patients with suprasellar germinoma.
Lee H; Lee JW; Cho HW; Choe YS; Lee KH; Choi JY; Sung KW; Moon SH
PLoS One; 2023; 18(7):e0288528. PubMed ID: 37440573
[TBL] [Abstract] [Full Text] [Related]
2. Surgeon-performed ultrasound changes surgical management in patients with thyroid cancer.
Tapia M; Chia C; Manji J; Magarey MJR; Flatman S
ANZ J Surg; 2022 Dec; 92(12):3268-3272. PubMed ID: 36151922
[TBL] [Abstract] [Full Text] [Related]
3. Prevalence of sarcopenia in patients with solid tumors: A meta-analysis based on 81,814 patients.
Surov A; Wienke A
JPEN J Parenter Enteral Nutr; 2022 Nov; 46(8):1761-1768. PubMed ID: 35633306
[TBL] [Abstract] [Full Text] [Related]
4. Histopathological Characteristics of N1b Papillary thyroid Carcinoma are Associated with Risk of Recurrence.
Carmel Neiderman NN; Duek I; Kuzmenko B; Ringel B; Warshavsky A; Muhanna N; Horowitz G; Fliss DM
World J Surg; 2022 Aug; 46(8):1917-1925. PubMed ID: 35543736
[TBL] [Abstract] [Full Text] [Related]
5. Molecular Variants and Their Risks for Malignancy in Cytologically Indeterminate thyroid Nodules.
Goldner WS; Angell TE; McAdoo SL; Babiarz J; Sadow PM; Nabhan FA; Nasr C; Kloos RT
Thyroid; 2019 Nov; 29(11):1594-1605. PubMed ID: 31469053
[No Abstract] [Full Text] [Related]
6. Risk of needing completion thyroidectomy for low-risk papillary thyroid cancers treated by lobectomy.
DiMarco AN; Wong MS; Jayasekara J; Cole-Clark D; Aniss A; Glover AR; Delbridge LW; Sywak MS; Sidhu SB
BJS Open; 2019 Jun; 3(3):299-304. PubMed ID: 31183445
[TBL] [Abstract] [Full Text] [Related]
7. Noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP): a review for clinicians.
Rosario PW; Mourão GF
Endocr Relat Cancer; 2019 May; 26(5):R259-R266. PubMed ID: 30913533
[TBL] [Abstract] [Full Text] [Related]
8. Magnetic detection of sentinel lymph node in papillary thyroid carcinoma: The MAGIC-PAT study results.
Baena Fustegueras JA; González FH; Calderó SG; de la Fuente Juárez MC; López SR; Riu FR; Petit NM; Álvarez PM; Torelló AL; Matias-Guiu X; Olsina Kissler JJ
Eur J Surg Oncol; 2019 Jul; 45(7):1175-1181. PubMed ID: 30905393
[TBL] [Abstract] [Full Text] [Related]
9. Controversies, Consensus, and Collaboration in the Use of
Tuttle RM; Ahuja S; Avram AM; Bernet VJ; Bourguet P; Daniels GH; Dillehay G; Draganescu C; Flux G; Führer D; Giovanella L; Greenspan B; Luster M; Muylle K; Smit JWA; Van Nostrand D; Verburg FA; Hegedüs L
Thyroid; 2019 Apr; 29(4):461-470. PubMed ID: 30900516
[TBL] [Abstract] [Full Text] [Related]
10. Evaluating the predicted impact of changes to the AJCC/TMN staging system for differentiated thyroid cancer (DTC): A prospective observational study of patients in South East Scotland.
Hulse K; Williamson A; Gibb FW; Conn B; Nixon IJ
Clin Otolaryngol; 2019 May; 44(3):330-335. PubMed ID: 30720920
[TBL] [Abstract] [Full Text] [Related]
11. Columnar Cell Variant of Papillary thyroid Carcinoma: Ultrasonographic and Clinical Differentiation between the Indolent and Aggressive Types.
Cho J; Shin JH; Hahn SY; Oh YL
Korean J Radiol; 2018; 19(5):1000-1005. PubMed ID: 30174490
[TBL] [Abstract] [Full Text] [Related]
12. Occult invasion of sternothyroid muscle by differentiated thyroid cancer.
Khan ZA; Mehta S; Sumathi N; Dhiwakar M
Eur Arch Otorhinolaryngol; 2018 Jan; 275(1):233-238. PubMed ID: 29181617
[TBL] [Abstract] [Full Text] [Related]
13. Cartilage invasion patterns in laryngeal cancer.
Gómez Serrano M; Iglesias Moreno MC; Gimeno Hernández J; Ortega Medina L; Martín Villares C; Poch Broto J
Eur Arch Otorhinolaryngol; 2016 Jul; 273(7):1863-9. PubMed ID: 26100029
[TBL] [Abstract] [Full Text] [Related]
14. New somatic mutations and WNK1-B4GALNT3 gene fusion in papillary thyroid carcinoma.
Costa V; Esposito R; Ziviello C; Sepe R; Bim LV; Cacciola NA; Decaussin-Petrucci M; Pallante P; Fusco A; Ciccodicola A
Oncotarget; 2015 May; 6(13):11242-51. PubMed ID: 25803323
[TBL] [Abstract] [Full Text] [Related]
15. Retrospective analysis of 18F-FDG PET/CT for staging asymptomatic breast cancer patients younger than 40 years.
Riedl CC; Slobod E; Jochelson M; Morrow M; Goldman DA; Gonen M; Weber WA; Ulaner GA
J Nucl Med; 2014 Oct; 55(10):1578-83. PubMed ID: 25214641
[TBL] [Abstract] [Full Text] [Related]
16. Value of ¹³¹I SPECT/CT for the evaluation of differentiated thyroid cancer: a systematic review of the literature.
Xue YL; Qiu ZL; Song HJ; Luo QY
Eur J Nucl Med Mol Imaging; 2013 May; 40(5):768-78. PubMed ID: 23242250
[TBL] [Abstract] [Full Text] [Related]
17. 131I SPECT/CT in the follow-up of patients with differentiated thyroid carcinoma.
Menges M; Uder M; Kuwert T; Schmidt D
Clin Nucl Med; 2012 Jun; 37(6):555-60. PubMed ID: 22614186
[TBL] [Abstract] [Full Text] [Related]
18. Factors associated with positive F-18 flurodeoxyglucose positron emission tomography before thyroidectomy in patients with papillary thyroid carcinoma.
Kim BS; Kim SJ; Kim IJ; Pak K; Kim K
Thyroid; 2012 Jul; 22(7):725-9. PubMed ID: 22524470
[TBL] [Abstract] [Full Text] [Related]
19. Investigation of V600E BRAF mutation in papillary thyroid carcinoma in the Polish population.
Brzeziańska E; Pastuszak-Lewandoska D; Wojciechowska K; Migdalska-Sek M; Cyniak-Magierska A; Nawrot E; Lewiński A
Neuro Endocrinol Lett; 2007 Aug; 28(4):351-9. PubMed ID: 17693984
[TBL] [Abstract] [Full Text] [Related]
20. Diagnostic accuracy and prognostic value of 18F-FDG PET in Hürthle cell thyroid cancer patients.
Pryma DA; Schöder H; Gönen M; Robbins RJ; Larson SM; Yeung HW
J Nucl Med; 2006 Aug; 47(8):1260-6. PubMed ID: 16883003
[TBL] [Abstract] [Full Text] [Related]
[Next]
